Prof Eliza Hawkes
Honorary Professorial Fellow
Department of Medicine
339 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP– but not Pola-R-CHP–treated patients with DLBCL
DOI: 10.1016/j.bneo.2026.1002642026
Journal article
End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study
DOI: 10.1111/bjh.706892026
Journal article
Older patients with lymphoma: navigating a landscape of clinical controversies and barriers to innovation
DOI: 10.3324/haematol.2025.2887002026
Journal article
Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
DOI: 10.1200/JCO-26-018002026
Journal article
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
DOI: 10.1200/JCO-26-009472026
Journal article
Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.
DOI: 10.3324/haematol.2026.3010082026
Journal article
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
DOI: 10.1182/bloodadvances.2026020012
RECENT SCHOLARLY WORKS
2026
Journal article
ABCL-1058: Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of the Antibody-Drug Conjugate ARC-02 as Monotherapy and in Combination With Rituximab in Adults With B-Cell Non-Hodgkin's Lymphoma
DOI: 10.1016/s2152-2650(26)02618-22026
Journal article
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
DOI: 10.1002/hem3.704432026
Journal article
POSTER: ABCL-1058: Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of the Antibody-Drug Conjugate ARC-02 as Monotherapy and in Combination With Rituximab in Adults With B-Cell Non-Hodgkin's Lymphoma
DOI: 10.1016/s2152-2650(26)01135-3